ea0032p78 | Bone and Osteoporosis | ECE2013
Tzioras Konstantinos
, Mizamtsidi Maria
, Chronaiou Aikaterini
, Vasiliou Georgia
, Tagara Sofia
, Vryonidou Andromachi
Introduction: Denosumab is a new pharmacotherapy option for postmenopausal osteoporosis. It is a human monoclonal antibody against RANKL, acting as an osteoprotegerin (OPG) analog. Recently, osteoprotegerin levels were found to be elevated in type two diabetes while insulin resistance was shown to be positively associated with decreased serum OPG levels, in healthy obese subjects. However, no study has been conducted in order to clarify the effect of anti-RANKL factors adminis...